Summit Therapeutics (SMMT) Q3 2024 earnings summary

Executive summary

• Ivonescimab achieved a 49% reduction in disease progression or death versus pembrolizumab in Phase III trials, with benefit across PD-L1 and histology subgroups and strong efficacy in multiple tumor types.

• Completed enrollment in the global Phase III HARMONI trial for EGFR-mutated advanced NSCLC; topline data expected mid-2025; FDA granted Fast Track Designation.

• Expanded HARMONI-3 Phase III trial to include non-squamous NSCLC, dual endpoints (PFS and OS), and increased sample size to 1,080 patients.

• Raised $235 million in private placement, boosting cash reserves to $487 million as of September 30, 2024, supporting clinical expansion.

• Entered strategic alliances, including with MD Anderson, and expanded licensing to new territories.

Financial highlights

• Ended Q3 2024 with $487 million in cash, cash equivalents, and short-term investments, up from $186.2 million at year-end 2023.

• Q3 2024 GAAP R&D expenses: $37.7 million; non-GAAP R&D: $31.9 million.

• Q3 2024 GAAP G&A expenses: $20.4 million; non-GAAP G&A: $6.8 million.

• Q3 2024 GAAP net loss: $56.3 million ($0.08/share); non-GAAP net loss: $36.9 million ($0.05/share).

• Net cash used in operating activities for the nine months ended September 30, 2024, was $93.4 million.

Outlook and guidance

• Sufficient cash to fund planned and expanded ivonescimab trials through 2025.

• Topline data from the global HARMONI Phase III trial expected mid-2025; HARMONI-7 trial initiation planned for early 2025.

• Continued expansion of clinical development into additional tumor types based on positive Phase II data.